The blood cells in NSCLC and the changes after RFA.

The blood cells in NSCLC and the changes after RFA. Int J Hyperthermia. 2020;37(1):753-762 Authors: Li Y, Wang D, Li X Abstract Lung cancer has attracted a lot of attention because of its high morbidity and mortality. The emergence of RFA provides a new treatment for unresectable NSCLC patients. In addition to killing in situ lung tumors, RFA also provides new immuno-activated antigens, for the treatment of lung cancer. It changes the tumor microenvironment and activates the entire immune system of patients. The peripheral blood cell count is easy to achieve and the blood cells are important in tumor immunity, which changes after RFA. On the one hand, the changes in blood cells identify the immune changes of NSCLC; on the other hand, it provides support and suspicion for the treatment of RFA. PMID: 32619369 [PubMed - as supplied by publisher]
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conditions:   Non-small Cell Lung Cancer;   Renal Cell Carcinoma Intervention:   Drug: Preoperative Ketorolac Sponsor:   Emory University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
CONCLUSION: Our data suggested that combined therapy with monensin might be a useful strategy for preventing EMT-mediated acquired drug resistance. PMID: 32736704 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Authors: Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ Abstract INTRODUCTION: Entrectinib, an oral pan-TRK, ALK, and ROS1 inhibitor is approved as a first-line treatment for NTRK-rearranged solid tumors and ROS1-rearranged non-small cell lung cancer (NSCLC). It has demonstrated clinical efficacy for patients harboring the relevant gene rearrangement in both systemic and intracranial disease, regardless of the tumor type. AREAS COVERED: In this review, the authors analyzed data from preclinical and clinical studies, the characteristics of entrectinib compared to those of other relevant inhibitor...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Non-small cell lung cancer (NSCLC) cells derived intracellular and extracellular programmed cell death ligand 1 (PD-L1) promoted cancer progression and drug resistance, and facilitated tumor immune evasion. Ho...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Publication date: Available online 1 August 2020Source: Pathology - Research and PracticeAuthor(s): Zong Wu, Wanqiu Li, Jiadong Li, Ying Zhang, Xinju Zhang, Yikun Xu, Yanping Hu, Qian Li, Qiangling Sun, Zhongliang Ma
Source: Pathology Research and Practice - Category: Pathology Source Type: research
CONCLUSIONS: Our study revealed the clinical significance of circPVT1 in NSCLC after cisplatin combined with gemcitabine chemotherapy. After treatment, circPVT1 expression was decreased and circPVT1 expression in chemotherapy-resistant patients was higher than in chemotherapy-sensitive patients. Decreased circPVT1 expression in chemotherapy-sensitive patients is more notable than in chemotherapy-resistant patients. Therefore, it is possible to determine the effect of therapy after receiving chemotherapy by detecting the expression of circRNA in serum. PMID: 32734834 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Authors: Philips BJ, Kumar A, Burki S, Ryan JP, Noda K, D'Cunha J Abstract Lung cancer is one of the most prevalent malignancies world-wide with non-small cell lung cancer (NSCLC) comprising nearly 80% of all cases. Unfortunately, many lung cancer patients are diagnosed at advanced stages of the disease with an associated poor prognosis. Recently, the Chinese herb root extract Triptolide/Minnelide (TL) has shown significant promise as a therapeutic agent for NSCLC treatment both in vitro and in vivo. The aim of this study was to investigate the underlying mechanism(s) of action regarding TL-induced cytotoxicity in ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Cancer evolves from a single cell that undergoes transformation and acquires a strong proliferative capacity through several genetic alterations, including somatic mutations, chromosomal copy-number alterations, dynamic changes in chromosome number and structure, and epigenetic instability (1,2). Cancer founder cells are characterized by a strong proliferative capacity; thus, they expand to compete with neighboring normal cells. This expansion is influenced by the surrounding tumor microenvironment, including the immune system (3,4).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Internal Medicine | Lung Cancer | Non-Small Cell Lung Cancer